Harness the Next Generation of Vectors to Guarantee Targeted, Specific, Efficient & Safe Gene Delivery
The 2nd Annual Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.
Industry pioneers from cutting edge biopharma and world-leading academic vectorology groups including Voyager Therapeutics, Spark Therapeutics, Dyno Therapeutics, Chameleon Biosciences, BioMarin and more will share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely.
Spanning a range of delivery approaches from cutting-edge AAV capsid optimisation, utilising lenti and other viral vectors, to innovative non-viral gene therapy approaches, this comprehensive event will enable you to reduce immunogenicity, improve tissue targeting, simplify manufacturing and enhance the safety profile of your approach.
Everything in gene therapy starts with delivery, so join this definitive, niche conference to delve into the details of vector design, engineering and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before.
Expert Speakers Include:






What’s New for 2022:

AI & Machine learning Pre-Conference Workshop
Get up to speed with the latest applications of machine learning and AI for vector engineering in our pre-conference primer. A 2 hour long intimate discussion led session, designed to act as your one stop shop for all things AI and machine learning hosted by leaders in the field, Dyno Therapeutics

Brand new Non-Viral track
Hosting more than 12 industry speakers aiming to uncover the pioneering work to accelerating non-viral delivery mechanisms. Jump into our non-viral track and here the latest developments in the field from speakers including Xalud Therapeutics, Code Bio, Gennao Bio, Poseida, Carmine Therapeutics, Intergalactic Therapeutics & more!

CMC Plenary session
Highlighting how biopharma are manufacturing high quality & quantities of next generation vectors. Delve into the latest developments in manufacturing to understand how the next generation of vectors are going to be produced for greater efficacy and safety with Ultragenyx, Voyager Therapeutics & Ask Bio